Business Context and Reporting Period
Processa Pharmaceuticals, Inc. (PCSA) filed this Form 8-K on May 16, 2022. The filing serves to provide current information regarding the Company's patent portfolio and to correct prior disclosures concerning the number of U.S. patents licensed from Elion.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is strictly informational regarding intellectual property assets.
Material Changes
The Company corrected previous disclosures to reflect the accurate count of licensed U.S. patents. The updated portfolio totals 24 U.S. patents, distributed among the following licensors:
- Concert: 9 patents
- Yuhan: 4 patents
- Aposense: 3 patents
- Elion: 2 patents
- Ocuphire: 6 patents
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of specific risks and contingencies beyond the correction of the patent count.
Investor Verification Checklist
- Verify the total count of 24 licensed U.S. patents against the Company's latest intellectual property disclosures.
- Confirm the specific breakdown of patents per licensor (Concert, Yuhan, Aposense, Elion, Ocuphire) to ensure alignment with licensing agreements.
- Review prior filings to understand the nature of the correction regarding Elion patents.